Jodi Sievers

Jodi Sievers has a diverse work experience in the field of corporate communications and investor relations. Jodi is currently serving as the Vice President of Corporate Communications at Coherus BioSciences since September 2022. Prior to this, they held the position of Vice President of Investor Relations & Corporate Communications at Rigel Pharmaceuticals Inc. from April 2021 to September 2022.

Before joining Rigel Pharmaceuticals, Jodi was the Senior Director of Corporate Affairs at Aimmune Therapeutics from June 2020 to April 2021. In this role, they were responsible for overseeing various corporate affairs programs, including corporate communications, media relations, employee communications, change management, and public relations.

Jodi has also worked at Nektar Therapeutics as the Director of Investor Relations & Corporate Communications from August 2010 to February 2020. Their responsibilities included developing and implementing corporate communications strategies, acting as a corporate contact for the investment community and reporters, and executing investor relations and media relations objectives.

Prior to joining Nektar Therapeutics, Jodi worked at Mahalex, Inc as a Principal in Biotech Pharma Communications. Jodi also has experience at Stiefel Laboratories, where they served in various roles including Senior Manager of eCommunications and Corporate Communications & Investor Relations Manager. Additionally, Jodi worked as a Consultant at Macroflux Corporation (now Zosano Pharma), where they focused on brand strategy development and investor relations.

Throughout their career, Jodi Sievers has demonstrated expertise in corporate communications, investor relations, media relations, and public relations, contributing to the success of the organizations they have worked for.

Jodi Sievers obtained a Bachelor of Arts degree in Economics from UC Santa Barbara between 1982 and 1985, with a minor in Art History and Philosophy.